Becton Dickinson & Co Stock Price, News & Analysis

The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.87 per common share, payable on September 30, 2022, to shareholders on record as of September 9, 2022. This results in an annual dividend rate of $3.48 per share, reflecting the company's commitment to returning value to its shareholders. BD continues to advance global health through innovative medical technology, ensuring safety and efficiency in healthcare delivery.

BD (Becton, Dickinson and Company) has completed its acquisition of Parata Systems, enhancing its presence in the pharmacy automation market valued at $600 million, projected to grow to $1.5 billion within a decade.

This acquisition aligns with BD's innovation strategy and aims to drive smart, connected care. The Parata portfolio will augment BD's Medication Management Solutions, addressing industry challenges such as clinician shortages and increased demand on pharmacy services.

BD (Becton, Dickinson and Company) will report its financial results for the third quarter of fiscal year 2022 on August 4, 2022, at 6:30 a.m. ET. The report will include summary financial information from the quarter ending June 30, 2022. An audio webcast will follow at 8 a.m. ET, discussing the results and operational updates. BD remains a leading global medical technology company, committed to improving health care through innovative solutions and technologies.

BD (Becton, Dickinson and Company) has appointed Rishi Grover as the new executive vice president and chief integrated supply chain officer, effective July 7, 2022. Grover, who brings over 20 years of experience in manufacturing and supply chain, previously held senior roles at Carrier. He will oversee Supply Chain, Operations, Procurement, Sustainability, and EHS teams and will be part of the BD Executive Leadership Team. Grover succeeds Alexandre Conroy, who is retiring after 31 years with the company.

BD (Becton, Dickinson and Company) has received CE marking for its BD MAX™ Respiratory Viral Panel (RVP), a diagnostic test that detects SARS-CoV-2, Influenza A + B, and RSV using a single nasal or nasopharyngeal swab. This test enhances diagnostic efficiency, crucial during flu season, by enabling quick differentiation and treatment for these viruses. The BD MAX™ System, which supports this assay, is widely utilized globally for various diagnostic tests. BD plans to seek Emergency Use Authorization from the FDA shortly.

BD (Becton, Dickinson and Company) has announced a voluntary recall of certain lots of Intraosseous Needle Set Kits, Manual Driver Kits, and Powered Drivers. The recall is due to potential issues that could lead to difficulty in needle assembly removal, failure of safety mechanisms, and functional loss of intraosseous access. These defects may cause delays in patient care or increase the risk of needlestick injuries. BD advises customers to review their inventory and temporarily halt usage until further notice.

BD (Becton, Dickinson and Company) announced a collaboration with Mayo Clinic Platform to access a vast collection of de-identified clinical data to enhance post-market surveillance of its products. This partnership aims to accelerate innovation, improve patient care, and leverage real-world data for insights beyond traditional clinical trials.

The Mayo Clinic Platform offers access to data from 10 million patients, including extensive lab results and clinical notes. BD plans to utilize advanced analytics and predictive modeling to enhance product development and regulatory submissions, ultimately improving patient outcomes.